Outcomes and complications of excimer laser surgery in patients with collagen vascular and other immune-mediated inflammatory diseases

PURPOSE

To assess refractive and visual outcomes and postoperative complications in a large number of patients with well-controlled collagen vascular and other immune-mediated inflammatory diseases.

SETTING

Optical Express, Glasgow, United Kingdom.

DESIGN

Retrospective case series.

METHODS

The files were reviewed of patients who had collagen vascular and other immune-mediated inflammatory diseases and who had excimer laser surgery between 2008 and 2015. In all cases, the disease was well controlled with no flare or symptoms for a minimum of 6 months preoperatively.

RESULTS

The study comprised 622 patients (1224 eyes) with 1 of the following underlying diseases: rheumatoid arthritis (50.6% of patients), systemic lupus erythematosus (19.5%), psoriatic arthritis (10.5%), sarcoidosis (10.0%), ankylosing spondylitis (6.4%), multiple sclerosis (1.9%), or scleroderma (1.1%). Laser in situ keratomileusis (LASIK) was performed in 1114 eyes (91.0%) and photorefractive keratectomy (PRK) in 110 eyes (9.0%). The mean follow-up was 10.9 months. The preoperative spherical equivalent ranged between -10.13 diopters (D) and +4.13 D (LASIK) and -9.50 D and +4.00 D (PRK). Postoperatively, 81.8% LASIK eyes and 82.3% PRK eyes were within ±0.50 D. The uncorrected distance visual acuity was 20/20 or better in 76.8% and 73.4%, respectively. Complications were mostly those that would be expected after excimer laser surgery in a population of patients without disease with the exception of 1 peripheral flap melt that responded to treatment with topical steroids.

CONCLUSION

Excimer laser surgery can be safely performed in patients with well-controlled collagen vascular or other immune-mediated inflammatory disease.

FINANCIAL DISCLOSURE

Dr. S.C. Schallhorn is a consultant to Abbott Medical Optics, Inc., Acufocus, Inc., and Carl Zeiss Meditec AG, and a global medical director for Optical Express. No other author has a financial or proprietary interest in any material or method mentioned.

Peripheral Ulcerative Keratitis following Laser in situ Keratomileusis

Purpose

We report a case of a patient with a history of glomerulonephropathy, not disclosed prior to laser in situ keratomileusis (LASIK), who developed severe postoperative peripheral ulcerative keratitis (PUK) soon after surgery.

Method

Case report.

Results

Within a week of surgery, the patient, who had no blepharitis or ocular surface disease, also developed diffuse lamellar keratitis (DLK) that was not contiguous with the PUK. Microbiologic evaluation of the flap interface disclosed no organisms, and no epithelial ingrowth was found. Both PUK and DLK resolved with topical and oral steroid therapy, and the patient's induced refractive error improved over the 12 months following LASIK.

Conclusions

Necrotizing keratitis has been described after LASIK surgery in patients with or without autoimmune disease. However, to our knowledge, there has been no case of PUK following LASIK. As shown by our patient's clinical course and the typical association of PUK with systemic conditions, patients with a history of atypical postinfectious sequelae may require additional preoperative counseling, vigilant postoperative monitoring, and possibly additional intervention. Because patients do not always divulge medical details, especially if an extraocular site was involved or illness occurred many years prior, this case demonstrates the importance of performing a diligent history that excludes autoimmune disorders or atypical postinfectious sequelae prior to proceeding with keratorefractive intervention.

Refractive surgery in systemic and autoimmune disease

Patients with underlying systemic disease represent challenging treatment dilemma to the refractive surgeon. The refractive error in this patient population is accompanied by a systemic disease that may have an ocular or even a corneal component. The literature is rather sparse about the use of laser refractive surgery (LRS) and such procedure is not approved by the United States Food and Drug Administration (FDA) in this patient population. Patients with collagen vascular disease, diabetes mellitus (DM), allergic and atopic disease, or human immunodeficiency virus (HIV) are never ideal for LRS. Patients with uncontrolled systemic disease or ocular involvement of the disease should not undergo LRS. However, a patient with well-controlled and mild disease, no ocular involvement, and not on multidrug regimen may be a suitable candidate if they meet stringent criteria. There is a need for a large, multicenter, controlled trial to address the safety and efficacy of LRS in patients with systemic disease before such technology can be widely adopted by the refractive surgery community.

Cogan syndrome presenting after uneventful laser in situ keratomileusis

We report 2 cases of Cogan syndrome that developed after uneventful laser in situ keratomileusis. In the first case, an 8-month postoperative biomicroscopy revealed bilateral interface neovascularization, white intrastromal deposits, and anterior chamber cells and flare. In the second case, white cell infiltration and neovascularization were observed in the deep corneal stroma of the patient's right eye 18 months postoperatively. Based on these observations, which are consistent with typical interstitial keratitis, and the patients' history of Meniere-like disease, such as vertigo and mild hearing loss, Cogan syndrome was diagnosed in both patients. Topical steroids were prescribed. Intensive treatments with corneal irrigation and topical steroids showed effective outcomes in both cases.

LASIK interface keratitis: epidemiology, diagnosis and care

PURPOSE OF REVIEW

Diffuse lamellar keratitis (DLK) is one of the more common interface complications occurs after laser in-situ keratomileusis (LASIK). The diagnosis can sometimes be challenging, as the differential diagnosis includes infectious keratitis, which requires a completely different treatment compared to DLK. This review assesses our current knowledge of the epidemiology, diagnosis and treatment of DLK.

RECENT FINDINGS

DLK occurs during the immediate postoperative period, but there are also late-onset cases. Early cases can occur in outbreaks, related to exogenous factors. Late-onset cases are most often related to inciting factors. Over time, case reports and series have reported DLK onset occurring further after surgery. It is probable that additional inciting factors will also be reported over time. Visual outcomes following DLK tend to be good when the condition is diagnosed properly and treated with intensive topical or systemic steroids, possibly combined with interface irrigation.

SUMMARY

DLK is a well recognized and well described complication occurring after LASIK. Associated inciting and risk factors and treatment algorithms have been described, but additional questions remain. Our knowledge and our patients will benefit from further research and development of evidence-based treatments.